Here are the DEF 14A proxy statements from Coya Therapeutics, Inc. (COYA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow COYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COYA filings page.
Coya Therapeutics is asking stockholders to vote at a virtual annual meeting on June 25, 2026. Investors are being asked to elect two Class I directors, Wilbur Ross and Dieter Weinand, to serve until the 2029 meeting, and to ratify Weaver and Tidwell, L.L.P. as independent auditor for 2026.
The proxy details board structure, committee membership and independence, executive and director compensation, and the company’s 2021 equity incentive plan. It also outlines ownership levels, with 23,457,183 common shares outstanding as of May 1, 2026, and explains how stockholders can attend and vote electronically.